{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-037209","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2025-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.067108+00:00","generated_at":"2026-05-16T13:48:03.347824+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Moleculin reports MIRACLE AML trial enrollment at 78% of 45-subject interim target","bullets":["Enrollment increased to 78% of target for first interim unblinding (up from 60% in Nov).","First unblinding will involve 45 subjects; treatment completion expected Q1 2026.","Consented subjects across seven countries; recruitment ongoing beyond the 78% mark.","Part A of trial (90 subjects) expected to complete enrollment in H1 2026.","Blinded response activity tracking within expected range per CEO commentary."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-037209","json":"https://secwatch.observer/filing/0001437749-25-037209.json","markdown":"https://secwatch.observer/filing/0001437749-25-037209.md","text":"https://secwatch.observer/filing/0001437749-25-037209.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925037209/0001437749-25-037209-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925037209/mbrx20251208_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:48:03.347824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}